HBM HOLDINGS-B (02142.HK): Preclinical Data Unveiled for First AI-Derived Candidate LET003, Showing Remarkable Fat Loss & Muscle Preservation Combined with Semaglutide

NewTimeSpace News: Hbm Holdings Limited (02142.HK) released a voluntary announcement on May 18, 2026, disclosing preclinical data of its first AI-developed candidate drug LET003 for obesity treatment.
LET003 is a potential best-in-class next-generation monoclonal antibody targeting activin receptors ACVR2A/2B, and the first dual-target blocking antibody against ACVR2A/2B developed based on the Hu-mAtrIx™ AI platform. It exhibits a substantially slower in-vivo clearance rate than many peer molecules, supporting equivalent therapeutic efficacy with longer dosing intervals or lower dosages.
In wild-type obese mouse models, after three weeks of weekly subcutaneous injection of semaglutide plus LET003, the combined treatment group saw a 76.0% drop in fat mass versus the control group, and a 34.7% reduction compared with the semaglutide monotherapy group, alongside a 5.7% increase in lean mass. The results prove that adding LET003 to semaglutide can greatly boost fat-losing efficacy and mitigate lean mass loss commonly associated with standalone semaglutide treatment.
In high-fat diet-induced obese human FcRn transgenic mouse models, the combination group recorded a 6.0% lower fat-to-body weight ratio and a 5.3% higher lean mass-to-body weight ratio relative to semaglutide monotherapy. In normal diet models, LET003 at 5 mg/kg achieved comparable lean mass gain effects to bimagrumab at 15 mg/kg.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.